Moderna (MRNA)
NASDAQ:MRNA

Moderna (MRNA) Stock Forecast & Price Target

13,418 Followers
See the Price Targets and Ratings of:

MRNA Analyst Ratings

Moderate Buy
14Ratings
8 Buy
6 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Moderna
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MRNA Stock 12 Months Forecast

Average Price Target

$200.38
▲(11.79% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Moderna in the last 3 months. The average price target is $200.38 with a high forecast of $506.00 and a low forecast of $101.00. The average price target represents a 11.79% change from the last price of $179.24.
Highest Price Target$506.00Average Price Target$200.38Lowest Price Target$101.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
SVB Securities
$101.00
Hold
-43.65%
Downside
Reiterated
Moderna (MRNA) Receives a Hold from SVB Securities
Goldman Sachs
$296.00
Buy
65.14%
Upside
Reiterated
Goldman Sachs Maintains Buy on Moderna, Raises Price Target to $296
Argus Research
$150.00
Buy
-16.31%
Downside
Reiterated
Why Moderna Shares Are Rising TodayAlso, Argus Research analyst Jasper Hellweg Wednesday maintainedModerna with a Buy and loweredthe price target from$180to$150.
Piper Sandler
$214.00
Buy
19.39%
Upside
Reiterated
Piper Sandler reiterates Overweight Rating on Moderna (MRNA), PT $214Piper Sandler analyst Edward A. Tenthoff reiterated an Overweight rating and $214.00 price target on Moderna (NASDAQ: MRNA)
Bank of America Securities
$180.00
Hold
0.42%
Upside
Reiterated
Ahead Of Modernas Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To MarketHow Phase 2 Flu Vaccine Could Pan Out: Moderna is due to announce Phase 2 data for its seasonal flu vaccine candidate, codenamed mRNA-1010, in the coming weeks, Meacham said.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

MRNA Financial Forecast

MRNA Earnings Forecast
Next quarter’s earnings estimate for MRNA is $4.97 with a range of $2.97 to $7.05. The previous quarter’s EPS was $2.53. MRNA beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.35% of the time in the same period. In the last calendar year MRNA has Outperformed its overall industry.
Next quarter’s earnings estimate for MRNA is $4.97 with a range of $2.97 to $7.05. The previous quarter’s EPS was $2.53. MRNA beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.35% of the time in the same period. In the last calendar year MRNA has Outperformed its overall industry.
MRNA Sales Forecast
Next quarter’s sales forecast for MRNA is $4.85B with a range of $3.53B to $5.58B. The previous quarter’s sales results were $3.31B. MRNA beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.99% of the time in the same period. In the last calendar year MRNA has Outperformed its overall industry.
Next quarter’s sales forecast for MRNA is $4.85B with a range of $3.53B to $5.58B. The previous quarter’s sales results were $3.31B. MRNA beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.99% of the time in the same period. In the last calendar year MRNA has Outperformed its overall industry.
MRNA Analyst Recommendation Trends
In the current month, MRNA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MRNA average analyst price target in the past 3 months is $200.38
In the current month, MRNA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MRNA average analyst price target in the past 3 months is $200.38

MRNA Stock Forecast FAQ

What is MRNA’s average 12-month price target, according to analysts?
Based on analyst ratings, Moderna’s 12-month average price target is $200.38.
    What is MRNA’s upside potential, based on the analysts’ average price target?
    Moderna has 11.79% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MRNA a Buy, Sell or Hold?
          Moderna has a conensus rating of Moderate Buy which is based on 8 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Moderna’s price target?
            The average price target for Moderna is $200.38. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $506.00 ,the lowest forecast is $101.00. The average price target represents 11.79% Increase from the current price of $179.24.
              What do analysts say about Moderna?
              Moderna’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis